Tüdőrák: vizsgálatok itt: Spanyolország
273 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 12.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
- Where
- A Coruña, Badalona, Barcelona, Jerez de la Frontera, Las Palmas de Gran Canaria, L'Hospitalet de Llobregat, Madrid, Málaga, Ourense, Palma, Santander, Santiago de Compostela, Sevilla, Valencia, Zaragoza
- Életkor
- 18 év and over
- People
- 356 worldwide
- Run by
- Astellas Pharma Global Development, Inc.
See details and how to joinNCT07566052 · EU 2025-524079-22-00 - 1/2. fázisTaking peopleA Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
- Where
- A Coruña, Barcelona, Madrid
- Életkor
- 12 év and over
- People
- 840 worldwide
- Run by
- Nuvalent Inc.
See details and how to joinNCT05384626 · EU 2024-514266-39-00 - 3. fázisTaking peopleA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Where
- A Coruña, Badajoz, Barcelona, Las Palmas de Gran Canaria, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga, Oviedo, Palma, Santander, Sevilla, Valencia, Valladolid
- Életkor
- 18 év to 100 év
- People
- 750 worldwide
- Run by
- Amgen
See details and how to joinNCT05920356 · EU 2022-501863-41-00 - 3. fázisTaking peopleStudy of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
- Where
- A Coruña, Barcelona, Jaén, Jerez de la Frontera, Las Palmas de Gran Canaria, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga, Sevilla, Valencia
- Életkor
- 18 év and over
- People
- 590 worldwide
- Run by
- Revolution Medicines, Inc.
See details and how to joinNCT06881784 · EU 2024-518154-16-00 - No phaseTaking peopleA Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice
- Where
- Albacete, Alcázar de San Juan, Alicante, Almería, Badajoz, Barakaldo, Barcelona, Bilbao, Ciudad Real, Granada, Guadalajara, Manresa, Murcia, Oviedo, Palma de Mallorca, Pontevedra, Puerto Real, Reus, Santa Cruz de Tenerife, Santiago de Compostela, Seville, Toledo, Valencia, Valladolid, Zaragoza
- Életkor
- 18 év and over
- People
- 700 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07284121 - 2. fázisTaking peopleA Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
- Where
- Barcelona, Logroño, Madrid
- Életkor
- 18 év and over
- People
- 105 worldwide
- Run by
- Verastem, Inc.
See details and how to joinNCT07659782 · EU 2026-526472-23-00 - 1/2. fázisTaking peopleA Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer
- Where
- Badalona, L'Hospitalet de Llobregat, Madrid, Málaga
- Életkor
- 18 év and over
- People
- 315 worldwide
- Run by
- Voronoi, Inc
See details and how to joinNCT07699328 · EU 2025-523122-40-00 - 1/2. fázisTaking peopleA Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
- Where
- Badalona, Barcelona, Madrid, Sevilla, Valencia
- Életkor
- 18 év and over
- People
- 320 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05789082 · EU 2023-507171-22-00 - 3. fázisTaking peopleA Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Where
- Barcelona, Las Palmas de Gran Canaria, Madrid, Málaga, Palma de Mallorca, Pamplona, Santander, Seville, Valencia
- Életkor
- 18 év and over
- People
- 600 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06793215 - 1. fázisTaking peopleA Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- Where
- Barcelona, Madrid
- Életkor
- 18 év and over
- People
- 540 worldwide
- Run by
- Pfizer
See details and how to joinNCT07090499 · EU 2025-521729-33-00 - 3. fázisTaking peopleA Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Where
- A Coruña, Badajoz, Badalona, Barcelona, Granada, Madrid, Palma, Sevilla, Valencia, Zaragoza
- Életkor
- 18 év and over
- People
- 680 worldwide
- Run by
- Pfizer
See details and how to joinNCT07144280 · EU 2025-521281-97-00 - 3. fázisTaking peopleA Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
- Where
- Barakaldo, Barcelona, Girona, Madrid, Málaga, Sevilla, Valencia, Zaragoza
- Életkor
- 18 év and over
- People
- 850 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07361497 · EU 2025-523576-23-00 - 1/2. fázisTaking peopleA Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
- Where
- A Coruña, Barcelona, Logroño, Madrid
- Életkor
- 18 év and over
- People
- 160 worldwide
- Run by
- TRIANA Biomedicines, Inc.
See details and how to joinNCT07491497 · EU 2025-524418-27-00 - 1. fázisTaking peoplePhase 1 Study of PF-08046033 in Advanced Solid Tumors
- Where
- Barcelona, Madrid
- Életkor
- 18 év and over
- People
- 250 worldwide
- Run by
- Pfizer
See details and how to joinNCT07519655 - 1/2. fázisTaking peopleA 2-part Phase 1/2 Open-label Trial on ODM-212
- Where
- Barcelona, Madrid
- Életkor
- 18 év and over
- People
- 229 worldwide
- Run by
- Orion Corporation, Orion Pharma
See details and how to joinNCT07563738 - 3. fázisTaking peopleA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Where
- A Coruña, Badajoz, Barakaldo, Barcelona, Jerez de la Frontera, Las Palmas de Gran Canaria, León, L'Hospitalet de Llobregat, Madrid, Málaga, Palma, Pamplona, Pozuelo de Alarcón, Santiago de Compostela, Sevilla, Valencia, Zaragoza
- Életkor
- 18 év and over
- People
- 1264 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06119581 · EU 2023-503412-33-00 - 1. fázisTaking peopleA Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- Where
- Barcelona, Madrid, Valencia
- Életkor
- 18 év and over
- People
- 575 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06400472 · EU 2024-511238-11-00 - 3. fázisTaking peopleA Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Where
- A Coruña, Badalona, Barcelona, Madrid, Majadahonda, Pamplona, Valencia
- Életkor
- 18 év and over
- People
- 444 worldwide
- Run by
- Bayer
See details and how to joinNCT06452277 · EU 2024-511319-91-00 - 1. fázisTaking peopleA Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Where
- L'Hospitalet de Llobregat, Madrid, Sevilla
- Életkor
- 18 év and over
- People
- 460 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00 - 2. fázisTaking peopleA Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- Where
- Barcelona, Las Palmas, Madrid, Málaga, Pamplona, Valencia
- Életkor
- 18 év and over
- People
- 200 worldwide
- Run by
- Jazz Pharmaceuticals
See details and how to joinNCT06695845 · EU 2024-516551-41-00 - 3. fázisTaking peopleStudy of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Where
- Badajoz, Barcelona, Hospitalet, Jerez de la Frontera, Las Palmas de Gran Canaria, Madrid, Málaga, Palma, Pamplona, Pozuelo de Alarcón, Santiago de Compostela, Seville, Valencia, Zaragoza
- Életkor
- 18 év and over
- People
- 700 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06890598 · EU 2024-512302-25-00 - 2. fázisTaking peopleA Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
- Where
- Barcelona, Hospitalet, Madrid, Seville
- Életkor
- 18 év and over
- People
- 254 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07492680 - 3. fázisTaking peopleA Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation
- Where
- A Coruña, Barcelona, Girona, Madrid, Pamplona, Sevilla
- Életkor
- 18 év and over
- People
- 65 worldwide
- Run by
- Dizal Pharmaceutical Co. Ltd.
See details and how to join2022-502959-54-00 · EU 2022-502959-54-00 - 1/2. fázisTaking peopleA Clinical study of MK-4716 in people with certain solid tumors (MK-4716-001)
- Where
- Barcelona, Madrid
- Életkor
- 18 év and over
- People
- 29
- Run by
- Merck Sharp & Dohme LLC
See details and how to join2025-522495-84-00 · EU 2025-522495-84-00 - 2. fázisTaking peopleA Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
- Where
- A Coruña, Alicante, Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Sevilla, Valencia
- Életkor
- 18 év and over
- People
- 520 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05498428 · EU 2023-505065-91-00